So far, a non-selective NOS inhibitor has been reported to worsen the mortality in a BLM-induced murine pulmonary fibrosis model [10] and accelerated pulmonary granuloma formation in a purified protein derivative murine model [24], another model of pulmonary fibrosis. This evidence concerns the gene NOS1 and pulmonary fibrosis.